Blood

Vol. 147, Issue 8 Issue 8 2026
16
Articles

Articles in this Issue

Glutathionylated leaky mitochondrial pores as target in AML

Diego Pereira-Martins, Jan Jacob Schuringa Feb 19, 2026 pp. 806-807 10.1182/blood.2025032167

De novo CD19− B-ALL: awareness of a rare entity in initial diagnosis

Tsigab Hagos, Chen Zhao Feb 19, 2026 pp. 902-902 10.1182/blood.2025031848

Incremental changes to improve outcomes in ALL

Mark R. Litzow Feb 19, 2026 pp. 801-802 10.1182/blood.2025031878

Dysbiosis and gastrointestinal GVHD: to treat or not to treat

Edmund K. Waller Feb 19, 2026 pp. 809-810 10.1182/blood.2025031542

Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation

Tianyi Ling, Cristiana O’Brien, Jonathan R. St-Germain et al. Feb 19, 2026 pp. 863-876 10.1182/blood.2025028933

Abstract Patients with acute myeloid leukemia (AML) have a poor 5-year survival rate, highlighting the need for the identification of new approaches to target this disease. AML is...

The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials

Maximilian Stahl, Amer M. Zeidan Feb 19, 2026 pp. 811-820 10.1182/blood.2025029727

Abstract Aside from allogeneic transplantation, the current standard-of-care approach for higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) remains monotherapy with a hypome...

Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation

Ekin Ece Gurer Kluge, Elisabeth Meedt, Julia Feicht et al. Feb 19, 2026 pp. 886-896 10.1182/blood.2025029402

Abstract Calprotectin, a calcium- and zinc-binding protein that comprises the subunits S100A8 and S100A9, has been extensively studied as a biomarker of gastrointestinal (GI) infla...

Thrombosis risk model for critically ill children

Feb 19, 2026 pp. 903-903 10.1182/blood.2026033091

Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial

Nicolas Boissel, Sylvie Chevret, Françoise Huguet et al. Feb 19, 2026 pp. 821-833 10.1182/blood.2025029611

Abstract The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL)-2014 trial evaluated an intensive, age-adapted protocol for adults aged 18 to 59 years with Philadelp...

Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation

Jessica Stewart, Blossom Damania Feb 19, 2026 pp. 848-862 10.1182/blood.2025029771

Abstract Epstein-Barr virus (EBV) infects over 90% of the global population and drives multiple aggressive B-cell malignancies, including Burkitt lymphoma, diffuse large B-cell lym...

Utility of peripheral blood testing for detection and surveillance of clonal hematopoiesis in predisposed individuals

Enrico Attardi, Nathan Gray, Sara Lewis et al. Feb 19, 2026 pp. 897-901 10.1182/blood.2024028042

Abstract In this study, 108 pediatric patients with bone marrow (BM) failure and leukemia predisposition were evaluated for presence of clonal hematopoiesis in peripheral blood (PB...

One ball, two hits

Holly Lee Feb 19, 2026 pp. 802-804 10.1182/blood.2025031561

Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models

Kodandaram Pillarisetti, Danlin Yang, Leopoldo Luistro et al. Feb 19, 2026 pp. 834-847 10.1182/blood.2025030027

Abstract In multiple myeloma (MM), cell-specific antigens are valuable targets for developing effective T-cell-engaging therapeutics that can provide good immune responses. Achievi...

Multisite validation of a venous thrombosis risk model in critically ill children through the CHAT Consortium

Julie Jaffray, Brian Branchford, Maua M. Alleyne et al. Feb 19, 2026 pp. 877-885 10.1182/blood.2025029841

Abstract Critically ill children are at a high risk for hospital-associated venous thromboembolism (HA-VTE). Developing a validated risk assessment model (RAM) to identify children...

Pediatric hospital-acquired thrombosis: time for a CHAT

Paul Monagle Feb 19, 2026 pp. 808-809 10.1182/blood.2025032330

A viral Achilles’ heel for EBV-positive lymphomas

Robert Yarchoan, Giovanna Tosato Feb 19, 2026 pp. 804-806 10.1182/blood.2025031851

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page